Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

Staff and admin costs around double of receipts from customers. Almost making less than they were during Covid so it really makes you wonder what sort of growth we are seeing here if any. Different excuse every quarter about what is impacting revenue and the fact they still haven't submitted their responses to the last round of questions from the FDA either makes one think they are incompetent seeing as it was initially submitted in September last year, or the product has some substantial flaws and questions being asked. The fact that there has been next to no growth anywhere else with any of their other products to me shows that we aint dealing with anything special here. Its enough of a concern for me to sell any remaining minimal holdings I have. The biggest concern is that if the FDA rejects their submission, this SP will drop to about 10c. With recent dilution, I really just dont see any value here anymore.
Good luck all holders.